This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue


Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.




NUCALA: Patients with zero exacerbations over 4.5 years

COLUMBA (4.5-year open-label study)1
Number of exacerbations* All Patients, N=347

Results are descriptive.

*Based on exacerbations reported from the time a patient enrolled in COLUMBA until study withdrawal (median duration 3.8 years).

Secondary Endpoint: Annualized exacerbation rate: 0.68 (95% CI: 0.60, 0.78).

NUCALA: Associated with sustained protection from exacerbations over 4 years

Post hoc analysis: COLUMBA (4.5-year open-label study)2

NUCALA: Lasting reduced OCS dose observed for an additional 52 weeks

Post hoc analysis: COSMOS (open-label extension study)4

Durability of OCS Dose Reduction*

Graph only includes patients who completed COSMOS.4

*Durability of response was defined as OCS dose reduction when combined with SIRIUS data.4

Adapted with permission from Elsevier HS Journal, Inc. ©2016

93% of patients from SIRIUS enrolled in COSMOS


  1. Data on file, GSK.
  2. Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742-1751.
  3. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-659.
  4. Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058-2070.e1.
  5. Ortega HG, Liu MC, Pavord ID, et al. mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-1207.
  6. Bel EH, Wenzel SE, Thompson PJ, et al, Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-1197.